Edgewise Therapeutics Inc (EWTX NASDAQ) stock market data APIs
$39.2824
-0.49(-1.2%)
as of October 30, 2026
Try our APIs with
free plan!
Edgewise Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Prev. Close
39.2824
Open
38.7924
High
39.5616
Low
38.01
52 wk Range
16.7-48.51
Market Cap
4 225 M
Shares Outstanding
109 M
Beta
0.355
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Edgewise Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Edgewise Therapeutics Inc data using free add-ons & libraries
Get Edgewise Therapeutics Inc Fundamental Data
Edgewise Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -216 768 992
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Edgewise Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -0.55
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Edgewise Therapeutics Inc News
New
Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says
Edgewise Therapeutics (EWTX) has attracted considerable investor interest in the upcoming phase 3 de PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
CHICAGO, October 21, 2026--(BUSINESS WIRE)--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm's continued expansi...
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Cytokinetics, Incorporated CYTK is making encouraging commercial progress with its lead drug, Myqorzo (aficamten), following its December 2025 approval for treating symptomatic obstructive hypertrophi...
Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?
Edgewise Therapeutics has dosed the first patient in EQUINOX-HFpEF, a Phase 2, randomized, double-blind, placebo-controlled trial of its oral cardiac sarcomere modulator EDG-15400 in adults aged 30 to...
Get Edgewise Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.